Brain Natriuretic Peptide (BNP) Usefulness In Elderly Dyspneic Patients (BED)

Usefulness of Measuring Plasma Brain Natriuretic Peptide for Diagnosis and Prognosis in Very Elderly Patients.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00658216

Acronym

BED

Enrollment

390

Registered

2008-04-14

Start date

2007-06-30

Completion date

2012-02-29

Last updated

2013-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Keywords

Diagnosis and prognosis, Very elderly population, Heart failure, Brain natriuretic peptide, Observational prospective study, Older, Dyspneic patients aged 80

Brief summary

The purpose of this study is to test the usefulness of measuring plasma brain natriuretic peptide (BNP) for diagnosis and prognosis in very elderly dyspneic patients.

Detailed description

Measurement of BNP concentration is approved for use in the diagnosis of heart failure (HF) in elderly patients below 80 years of age. The value of plasma BNP assays as diagnostic tools has not been determined in very elderly populations because the plasma BNP increases with age. This large, multicenter, prospective, observational, study in 300 participants is aimed to prospectively test the usefulness of measuring plasma BNP for diagnosis of HF in dyspneic patients aged 80 and older.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

80 Years to No maximum

Healthy volunteers

Inclusion criteria

* acute dyspnea * crackles on lung auscultation, * hypoxemia, * right-sided signs.

Exclusion criteria

* no

Design outcomes

Primary

Measure	Time frame
Plasma BNP levels at T0 to test the optimal values of measuring plasma BNP for diagnosis of HF in patients older than 80 years.	6 months

Secondary

Measure	Time frame
Plasma BNP levels at 3 times (T0, T48, Tend) to test the usefulness of measuring plasma BNP : 1.at T0 : in diagnosing HF using a 2-threshold up-and down-approach	6 months
2.at T48 : in diagnosing and prognosing HF using a 2nd assay after 48 hours of treatment	6 months
3.at Tend : in prognosing HF using a 3rd assay after the acute phase (composite criteria)	6 months

Countries

France

Outcome results